



Official Air Force Missile Operator Duty (MOD – 13N) Approved Medications Quick Reference List Effective: 24 MAY 2018

(Note: Missile Operator Medications list shall be reviewed prior to initiation of new medications; this list supersedes the medication list dated 1 July 2015)

The approved medication list consists of drugs for acute and chronic conditions, listed by generic name under one of three categories, based on whether they may be prescribed without DNIA/C, may be prescribed by the flight surgeon without a waiver, or require a waiver. At the end of the document are listed a number of drugs which are known to be unacceptable for MOD. Request for waiver of such drugs is highly unlikely.

A large number of FDA-approved prescription drugs are not listed under either section. If such drugs are used for acute conditions, it should be assumed that the drug is disqualifying for MOD duty, with the MOD member returning to alert/controlling status after the condition has resolved, the medication has been discontinued, and its effects have dissipated, which usually entails one additional day (the “24-hour rule”). For chronic conditions, most common conditions are treatable by one or more of the listed drugs, and use of these drugs is likely to receive favorable consideration and a more expeditious result. If the MOD member is intolerant of or inadequately controlled by a listed medication, but is successfully treated by a non-listed drug, a waiver request for that drug may be submitted through AFGSC/SGP to AFMSA. Such requests are not delegated for initial or renewal waivers. All medications and immunizations use by MOD personnel must be FDA approved. MOD will use the “Official Air Force Aerospace Medicine Approved Medications: Over the Counter (OTC) Medications Aircrew Are Allowed to Take Without Flight Surgeon Approval” for OTC medications.

Members pending waiver action must be DNIA/C until waiver has been granted. Verbal waivers are NOT authorized. Consult Aerospace Medicine Waiver Guide prior to waiver submission. Waivers for non-FDA approved medications will not be considered.

Note that while a specific drug may be acceptable without waiver, the treated condition may still require waiver.

SUMMARY OF CHANGES:

All ophthalmic drops no longer require waiver for medication use alone. Underlying condition may still require waiver. MOD will use the “Official Air Force Aerospace Medicine Approved Medications: Over the Counter (OTC) Medications Aircrew Are Allowed to Take Without Flight Surgeon Approval” for OTC medications. Minor spelling and format updates.

| Category | Medication | | Diagnosis or Utilization | No DNIA/C Or Waiver | DNIA/C (No Waiver Required) | | DNIA/C (Waiver Required) | Notes |
|----------|--|---|---|---------------------|-----------------------------|--------------------------------------|--------------------------|--|
| | Generic Name (Oral Preparation Unless Specified Otherwise) | Trade Name (Not Inclusive) | | | For Ground Trial | Symptoms Controlled (No Side Effect) | | |
| Card | ACE Inhibitors | Lotensin, Capoten, Vasotec, Monopril, Zestril, Altase | Hypertension | | | X | | For use as a single agent or in combination with other approved antihypertensive. DNIA/C for first 7 days of use (minimum) until potential for idiosyncratic reaction has been ruled out and average blood pressure is < 160/100. A dose adjustment also requires a 7 day DNIA/C period. |
| Gen | Acetaminophen | Tylenol | Pain (Acute Use) | X | | | | DNIA/C is not required for occasional OTC use to provide relief from minor self-limiting conditions. |
| Gen | Acetaminophen | Tylenol | Pain (chronic use) | | | X | | DNIA/C until potential for idiosyncratic reaction has been ruled out and pain/inflammation control is achieved. |
| Gen | Acupuncture | Seirin needle, ASP needle | Pain (acute condition use) | X | | | | Minimum of 2 hours ground trial at initiation of therapy to ensure idiosyncratic reaction is ruled out. After initial ground trial, no DNIA/C required unless underlying condition interferes with MOD duties. Auricular ASP needles may be retained during MOD duty performance. |
| Gen | Acupuncture | Seirin needle, ASP needle | Pain (chronic use) | X | | | | |
| Gen | Acupuncture | Seirin needle, ASP needle | Chronic medical condition (i.e. PTSD, OA) | X | | | | |
| Derm | Acyclovir | Zovirax | HSV (Treatment and Suppression) | | X | | | DNIA/C until potential for idiosyncratic reaction has been ruled out. |
| Derm | Acyclovir (Topical) | Zovirax (Topical) | HSV | X | | | | DNIA/C not required unless condition or medication interferes duties. |

| Category | Medication | | Diagnosis or Utilization | No DNIA/C Or Waiver | DNIA/C (No Waiver Required) | | DNIA/C (Waiver Required) | Notes |
|----------|--|---|--|---------------------|-----------------------------|--------------------------------------|--------------------------|--|
| | Generic Name (Oral Preparation Unless Specified Otherwise) | Trade Name (Not Inclusive) | | | For Ground Trial | Symptoms Controlled (No Side Effect) | | |
| Gen | Adalimumab | Humira | Reactive Arthritis/ Rheumatoid Arthritis/ Psoriasis and Psoriatic Arthritis/ Ankylosing Spondylitis/ Ulcerative Colitis*, Crohns* | | | | X | Submit for waiver after potential for idiosyncratic reaction has been ruled out and control is maintained. Restricted Deployability, see Waiver Guide . Adalimumab Background Paper *Consult Waiver Guide for use in IBD patients. |
| Derm | Adapalene 0.1% Gel (topical) | Differin | Acne Vulgaris | X | | | | DNIF not required unless condition or medication interferes with MOD duties. Adapalene Background Paper |
| Pulm | Albuterol | Proventil | Asthma | | | | X | Requires IRILO/MEB submission prior to waiver. |
| MS | Alendronate | Fosamax | Osteoporosis (Prophylaxis and Treatment) | | X | | | DNIA/C until potential for idiosyncratic reaction has been ruled out and patient tolerates medication well. Take on non-alert days, if possible, or with food at least 30 minutes before duty. |
| GU | Alfuzosin | Uroxatral | BPH | | | | X | Max dose 10 mg daily. Rapaflow is first line agent and does not require waiver. See Alfuzosin Paper . |
| MS | Allopurinol | Zyloprim | Gout and Urolithiasis | | | X | | For urolithiasis either alone or in combination with thiazide (hydrochlorothiazide or chlorothiazide). |
| Infect | Amantadine | Symmetrel | Antiviral use only | | | X | | DNIA/C until the potential for idiosyncratic reaction has been ruled out and underlying condition does not interfere with duties. |
| Gen | Anesthetic Agents (Local or Regional) | | Surgical Procedures/Dental Procedures | | | X | | DNIA/C for at least 8 hours after receiving a local or regional anesthetic agent. Verbal DNIA/C and automatic return to status after 8 hours is authorized. Re-examination and return to status 2992 not required unless unexpected side-effects or complications occur. |
| Card | Angiotensin Receptor Blocker (ARB) | Atacand, Avapro, Cozaar, Micardis, Diovan | Hypertension | | | X | | For use as a single agent or in combination with other approved antihypertensive. DNIA/C for first 7 days of use (minimum) until potential for idiosyncratic reaction has been ruled out and average blood pressure is < 160/100. |
| Card | ARB + Calcium Channel Blocker | | Hypertension | | | X | | For use as a single agent or in combination with other approved antihypertensive. DNIA/C for first 7 days of use (minimum) until potential for idiosyncratic reaction has been ruled out and average blood pressure is < 160/100. A dose adjustment also requires a 7 day DNIA/C period. |

| Category | Medication | | Diagnosis or Utilization | No DNIA/C Or Waiver | DNIA/C (No Waiver Required) | | DNIA/C (Waiver Required) | Notes |
|------------|---|---|--|---------------------|-----------------------------|--------------------------------------|--------------------------|--|
| | Generic Name (Oral Preparation Unless Specified Otherwise) | Trade Name (Not Inclusive) | | | For Ground Trial | Symptoms Controlled (No Side Effect) | | |
| Card | ARB + Diuretic | | Hypertension | | | X | | For use as a single agent or in combination with other approved antihypertensive. DNIA/C for first 7 days of use (minimum) until potential for idiosyncratic reaction has been ruled out and average blood pressure is < 160/100. A dose adjustment also requires a 7 day DNIA/C period. |
| Infections | Antibiotics (All oral, topical, otic and ophthalmic except Minocycline) | | Acute or chronic infection | | | X | | DNIA/C until the potential for idiosyncratic reaction has been ruled out and underlying condition does not interfere with duties. Chronic underlying condition may require waiver. |
| Derm | Antibiotics (Topical) | | Acne | X | | | | DNIA/C not required unless condition or medication interferes with MOD duties. |
| Derm | Antifungals (Topical) | | Dermatomycosis | X | | | | DNIA/C not required unless condition or medication interferes with duties. |
| Infections | Antiparasitic | Albenza, Vermox | | | | X | | DNIA/C for first 7 days of use (minimum) until potential for idiosyncratic reaction has been ruled out. |
| Derm | Antiseptics (Topical) | | Acute Injury | X | | | | DNIA/C not required unless condition or medication interferes with duties. |
| Gen | Aspirin | Ecotrin | Pain | X | | | | DNIA/C is not required for occasional OTC use to provide relief from minor self-limiting conditions. |
| Gen | Aspirin | Bayer Aspirin | Prophylaxis | | X | | | Single ground trial is required for members who have never previously taken aspirin; 81 mg or 325 mg once daily for prophylactic therapy as clinically indicated. Underlying disqualifying condition (when present) continues to require waiver. |
| Gen | Atovaquone/ Proguanil (Combination) | Malarone | Malaria Prophylaxis (2 nd Line) | | X | | | Single dose ground trial required; Malarone (250 mg atovaquone/100 mg proguanil) daily beginning 1-2 days prior to travel; ending 7 days after exposure (Reminder: last 7 days of Malarone should be taken with primaquine followed by another 7 days of primaquine alone); Malarone Background Paper . |
| ENT | Azelastine | Astelin Optivar | Vasomotor Rhinitis Allergic-Conjunctivitis | | | X | | Third line agent, trial of nasal steroid and Claritin/Allegra first. Minimum 72 hours ground trial at initiation of therapy and adequate control of rhinitis is required. |
| Derm | Benzyl Peroxide (Topical) | | Acne | X | | | | DNIA/C not required unless condition or medication interferes with duties. |
| Card | Betablockers | Tenormin, Lopressor, Inderal, Toprol, Coreg | Hypertension | | | X | | For use as a single agent or in combination with other approved antihypertensive. DNIA/C for first 7 days of use (minimum) until potential for idiosyncratic reaction has been ruled out and average blood pressure is < 160/100. A dose adjustment also requires a 7 day DNIA/C period. |
| Card | Betablockers | Tenormin, Lopressor, Inderal, Toprol, Coreg | Headaches | | | | X | For use as a single agent or in combination with other approved antihypertensive. DNIA/C for first 7 days of use (minimum) until potential for idiosyncratic reaction has been ruled out and average blood pressure is < 160/100. A dose adjustment also requires a 7 day DNIA/C period. |

| Category | Medication | | Diagnosis or Utilization | No DNIA/C Or Waiver | DNIA/C (No Waiver Required) | | DNIA/C (Waiver Required) | Notes |
|-----------|--|---|--|---------------------|-----------------------------|--------------------------------------|--------------------------|--|
| | Generic Name (Oral Preparation Unless Specified Otherwise) | Trade Name (Not Inclusive) | | | For Ground Trial | Symptoms Controlled (No Side Effect) | | |
| Ophthal | Betaxolol Drops | Betoptic | Glaucoma | | | X | | DNIA/C until potential for idiosyncratic reaction has been ruled out. Underlying condition may require waiver in which case, DNIA/C until waiver approved. |
| Psych | Bupropion | Wellbutrin SR or XL | Depression or other waivable diagnosis | | | | X | Max dose 450 mg/day. Waiver will not be considered until member is on medication with stable dose and clinically asymptomatic for at least six months. |
| Gen | Bupropion | Zyban | Smoking Cessation | | X | | | Two week ground trial required. |
| Card | Calcium Channel Blockers | Norvasc, Plendil, Cardene, Adalat, Procardia, Cardizem, Calan | Headaches | | | X | | DNIA/C for first 7 days of use (minimum) until potential for idiosyncratic reaction has been ruled out. A dose adjustment also requires a 7 day DNIA/C period. |
| Card | Calcium Channel Blockers | Norvasc, Plendil, Cardene, Adalat, Procardia, Cardizem, Calan | Hypertension | | | | X | For use as a single agent or in combination with other approved antihypertensive. DNIA/C for first 7 days of use (minimum) until potential for idiosyncratic reaction has been ruled out and average blood pressure is < 160/100. A dose adjustment also requires a 7 day DNIA/C period. |
| Derm | Calcipotriene Ointment | Dovonex | Psoriasis | | X | | | DNIA/C until potential for idiosyncratic reaction has been ruled out. |
| ENT | Cetirizine | Zyrtec | Mild Allergic Rhinitis | | | X | | Minimum 72 hrs ground trial at initiation of therapy. Third line agent, trial of nasal steroid and Clartin/Allegra required first. |
| Gen | Chloroquine | Aralen | Malaria prophylaxis | | X | | | Single dose ground trial required; 500 mg tablet (300 mg base) once weekly beginning 1-2 weeks prior to travel; ending 4 weeks after exposure (Reminder: last 2 weeks should be taken with primaquine). |
| Dental | Chlorhexadine Gluconate | Peridex | Gingivitis | X | | | | DNIA/C not required unless condition interferes with duties. |
| Gen | Cholestyramine | Questran | Hyperlipidemia | | X | | | DNIA/C until potential for idiosyncratic reaction has been ruled out. |
| Derm | Ciclopirox (Topical) | Loprox | Dermatomyces, seborrheic dermatitis | X | | | | DNIA/C not required unless condition or medication interferes with duties. |
| Prophylax | Ciprofloxacin | Cipro | BW Prophylaxis | | X | | | Ciprofloxacin may be used operationally after monitored ground trial (500 mg every 12 hours for 2 doses with 48 hrs DNIA/C documented in medical records) in event of BW incident for post-exposure treatment and prophylaxis for inhalational anthrax; Cipro Policy Letter . |
| Psych | Citalopram | Celexa | Depression or other waivable diagnoses | | | | X | Max dose 40 mg/day. Waiver will not be considered until member is on medication with stable dose and clinically asymptomatic for at least six months. |
| GU | Clomiphene | Clomid | Infertility | | X | | | DNIA/C until potential for idiosyncratic reaction has been ruled out. |
| Gen | Colestipol | Colestid | Hyperlipidemia | | X | | | Minimum 7-day ground trial. A dose adjustment also requires a 7 day observation period. |
| GU | Contraceptives (Implantable) | Norplant, Implanon, Mirena | Contraception | | X | | | Minimum of 7-days ground trial is required. |

| Category | Medication | | Diagnosis or Utilization | No DNIA/C Or Waiver | DNIA/C (No Waiver Required) | | DNIA/C (Waiver Required) | Notes |
|-----------|---|--|--|---------------------|-----------------------------|--------------------------------------|--------------------------|--|
| | Generic Name (Oral Preparation Unless Specified Otherwise) | Trade Name (Not Inclusive) | | | For Ground Trial | Symptoms Controlled (No Side Effect) | | |
| GU | Contraceptives (Injectable) | DepoProvera | Contraception | | X | | | Minimum of 7-days ground trial is required. |
| GU | Contraceptives (Insertable) | Nuvaring | Contraception | | X | | | Minimum of 7-days ground trial is required. |
| GU | Contraceptives (Oral) | | Contraception | | X | | | Minimum of 7-days ground trial is required. Changes of dosage or preparation requires an additional 7-day observation period. |
| GU | Contraceptives (Transdermal/subdermal) | | Contraception | | X | | | Minimum of 7-days ground trial is required. |
| ENT | Cromolyn (Nasal) | Crolom | Mild Allergic, Non-allergic, or Vasomotor Rhinitis | X | | | | Underlying symptoms may require DNIA/C. |
| Ophthal | Cyclosporine Drops | Restasis | | | X | | | Per MSD not disqualifying for MOD; underlying symptoms may require DNIA/C. |
| Gen | Dextroamphetamine/Scopolamine | Dex/Scop | Airsickness | | X | | | For airsickness during transport to launch facility. |
| Gen | Dietary/ Herbal/ Nutritional Supplements Multivitamin Folate | | Wellness | X | | | | Dietary, herbal, and nutritional supplements may generally be used by MOD personnel without Flight Surgeon approval, provided the product is used in accordance with manufacturers' directions for its intended use and not in violation of Air Force policy. MOD personnel are required to consult with the flight surgeon whenever the member experiences adverse reactions which may affect the member's ability to perform MOD. Nutritional Supplement Policy Letter ; Ephedra Policy Letter ; SF 600 Overprint (optional tool for convenience) Human Performance Resource Center |
| Card | Diuretics | Hydrochlorothazide or HCTZ in combination with triamterene | Hypertension | | | X | | For use as a single agent or in combination with other approved antihypertensive. DNIA/C for first 7 days of use (minimum) until potential for idiosyncratic reaction has been ruled out and average blood pressure is < 160/100. A dose adjustment also requires a 7 day DNIA/C period. |
| Card | All other Diuretics or Diuretic Combinations | | Hypertension | | | | X | For use as a single agent or in combination with other approved antihypertensive. DNIA/C for first 7 days of use (minimum) until potential for idiosyncratic reaction has been ruled out and average blood pressure is < 160/100. A dose adjustment also requires a 7 day DNIA/C period. |
| GU | Doxazosin Mesylate | Cardura | BPH Only | | | | X | Not to be used for HTN. Minimum 7-day ground trial. A dose adjustment also requires a 7 day DNIA/C period. Rapaflo is first line agent not requiring a waiver. |
| Prophylax | Doxycycline | Vibramycin | BW Prophylaxis (2 nd Line) | X | | | | Should the individual develop an idiosyncratic reaction to Ciprofloxacin; Doxycycline (100 mg, twice daily) is the recommended prophylaxis of choice (in the absence of contraindications). |

| Category | Medication | | Diagnosis or Utilization | No DNIA/C Or Waiver | DNIA/C (No Waiver Required) | | DNIA/C (Waiver Required) | Notes |
|-----------|--|----------------------------|---|---------------------|-----------------------------|--------------------------------------|--------------------------|---|
| | Generic Name (Oral Preparation Unless Specified Otherwise) | Trade Name (Not Inclusive) | | | For Ground Trial | Symptoms Controlled (No Side Effect) | | |
| Prophylax | Doxycycline | Vibramycin | Malaria Prophylaxis | X | | | | 100 mg daily beginning 1-2 days prior to travel; ending 4 weeks after exposure (Reminder: last 2 weeks should be taken with primaquine) |
| Prophylax | Doxycycline | Vibramycin | Prophylaxis Against Diarrhea | X | | | | 100 mg administered daily during period of exposure and for at least 2 days following exposure for prophylaxis against diarrhea in deployed personnel; total period of use not to exceed 2 weeks. |
| GU | Doxycycline | Vibramycin | Suppressive Therapy for Chronic or Recurrent Prostatitis / Cystitis | | | X | | DNIA/C until potential for idiosyncratic reaction has been ruled out and control is maintained. |
| Endo | Eplerenon | Inspra | Hyperaldosteronism | | | | X | Submit for waiver after potential for idiosyncratic reaction has been ruled out and control is maintained. Eplerenone and Spironolactone Background Paper . |
| Psych | Escitalopram | Lexapro | Depression or other waivable diagnoses | | | | X | Max dose 20 mg/day waiver will not be considered until member is on medication with stable dose and clinically asymptomatic for at least six months. |
| Endo | Estrogen (Alone or with Progestin) | | Contraception/ Hormone Replacement Therapy | | X | X | | Minimum of 7-days ground trial is required. Changes of dosage or preparation requires an additional 7-day DNIA/C period. |
| Endo | Estrogen (Alone or with Progestin) (Topical) | | Contraception/ Hormone Replacement Therapy | | X | X | | Minimum of 7-days ground trial is required. Changes of dosage or preparation requires an additional 7-day DNIA/C period. |
| Gen | Etanercept | Enbrel | Rheumatological Diseases | | | | X | Nondeployable medication. Requires IRILO/MEB prior to waiver submission. Submit for waiver after potential for idiosyncratic reaction has been ruled out and control is maintained. Etanercept Background Paper |
| Endo | Etonogestrel/Ethinyl Estradiol (vaginal ring) | NuvaRing | Contraception | | X | | | Minimum of 7-days ground trial is required; changes of dosages and/or preparation requires an additional 7-day DNIA/C period. |
| Gen | Ezetimibe | Zetia | Hyperlipidemia (2 nd Line) | | X | | | DNIA/C for 3 days to rule out potential for idiosyncratic reaction; Ezetimibe Background Paper . |
| Gen | Ezetimibe/Simvastatin | Vytorin | Hyperlipidemia | | X | | | DNIA/C for 3 days to rule out potential for idiosyncratic reaction; Ezetimibe Background Paper . |
| Gen | Fenofibrate | Tricor | Hyperlipidemia | | X | | | Minimum of 7-days ground trial is required. Changes of dosage or preparation requires an additional 7-day DNIA/C period. |
| Gen | Ferrous Sulfate | | Iron Deficiency Anemia | X | | | | Underlying conditions or symptoms may require waiver. |

| Category | Medication | | Diagnosis or Utilization | No DNIA/C Or Waiver | DNIA/C (No Waiver Required) | | DNIA/C (Waiver Required) | Notes |
|----------|--|---|---|---------------------|-----------------------------|--------------------------------------|--------------------------|--|
| | Generic Name (Oral Preparation Unless Specified Otherwise) | Trade Name (Not Inclusive) | | | For Ground Trial | Symptoms Controlled (No Side Effect) | | |
| ENT | Fexofenadine | Allegra | Mild Allergic Rhinitis | | | X | | Minimum 72 hrs ground trial at initiation of therapy and adequate control of symptoms. |
| GU | Finasteride | Proscar | Benign Prostatic Hyperplasia | X | | | | Underlying conditions or symptoms may require waiver. |
| GU | Finasteride (1mg) | Propecia | Hair Loss | | X | | | DoD policy prohibits purchase of this drug for treatment hair loss using DoD funds. DNIA/C until potential for idiosyncratic reaction has been ruled out and control is maintained, then submit for waiver. Finasteride Background Paper |
| Derm | Fluconazole | Diflucan | Fungal infection | | X | | | |
| GI | Folate | | Sprue | | | | X | DNIA/C until potential for idiosyncratic reaction has been ruled out and control is maintained, then submit for waiver. |
| Gen | Gemfibrozil | Lopid | Hyperlipidemia | | X | | | DNIA/C until potential for idiosyncratic reaction has been ruled out. |
| GI | H-2 Blockers and PPI's | Aciphex, Nexium, Pepcid, Prevacid, Prilosec, Protonix, Zantac | GERD | | | X | | DNIF until potential for idiosyncratic reaction has been ruled out (minimum 3 days) and symptoms controlled. |
| GI | H-2 Blockers and PPI's | Aciphex, Nexium, Pepcid, Prevacid, Prilosec, Protonix, Zantac | PUD | | | | X | Submit for waiver after potential for idiosyncratic reaction has been ruled out and control is maintained. |
| Gen | Hyaluronate Derivatives | Synvisc, Synvisc-One, Euflexxa, Hyalgan, Orthovisc | Osteoarthritis pain | | | X | | For intra-articular injection only. 48hrs post-injection DNIA/C required. Use of this medication does not require waiver; however, depending on severity, underlying condition MAY require waiver. |
| Gen | Hydrochlorothiazide | Hydrodiuril | Urolithiasis | | | | X | For urolithiasis: either alone or in combination with allopurinol or oral potassium supplements. Submit for waiver after potential for idiosyncratic reaction has been ruled out and control is maintained. |
| Gen | Hydroxychloroquine | Plaquenil | Arthritis | | | | X | DNIA/C until potential for idiosyncratic reaction has been ruled out and control is maintained, then submit for waiver. |
| Derm | Imiquimod (Topical) | Aldara, Zyclara | Warts, actinic keratosis, basal cell cancer | X | | | | DNIF not required unless condition or medication interferes with life support gear or flying duties. Localized inflammatory reactions at the site of application are common, and should be considered prior to initiation of therapy. |
| Immuno | Immunization | | Wellness | X | | | | Adverse reactions are rare. Access to medical care on the ground is recommended for a period of 4 hours for all personnel, unless operational needs dictate otherwise. Recommend timing live immunizations such that side effects, if present, will have minimal operational impact. This guidance also applies to JEV (IXIARO). |
| Immuno | Immunotherapy | | Allergy | | X | | | A 4-hour verbal DNIA/C is required after each injection; MOD crew will not deploy on immunotherapy. |

| Category | Medication | | Diagnosis or Utilization | No DNIA/C Or Waiver | DNIA/C (No Waiver Required) | | DNIA/C (Waiver Required) | Notes |
|----------|--|----------------------------|---|---------------------|-----------------------------|--------------------------------------|--------------------------|---|
| | Generic Name (Oral Preparation Unless Specified Otherwise) | Trade Name (Not Inclusive) | | | For Ground Trial | Symptoms Controlled (No Side Effect) | | |
| Gen | Infliximab | Remicade | Ankylosing spondylitis, psoriatic arthritis, IBD, psoriasis | | | | X | No initial MOD waivers. Submit for waiver after potential for idiosyncratic reaction has been ruled out and control is maintained. Psoriasis when other medications have failed. Consult Waiver Guide for use in IBD patients. Restricted deployability, see Waiver Guide. See Infliximab (Remicade) background paper |
| Pulm | INH-Rifapentine | Priftin | Latent TB | | | | X | Directly Observed Therapy regimens only, IAW CDC/IDSA recommendations. Prior to deployment ensure PH clearance for completion of DOT. |
| Pulm | Ipratropium | Atrovent | Asthma | | | | X | Requires IRILO/MEB submission prior to waiver. |
| ENT | Ipratropium nasal | Atrovent nasal | Allergic/non-allergic rhinitis | | X | | | Minimum 7-day ground trial. A dose adjustment also requires a 7 day observation period. |
| Pulm | Isoniazid (INH) | Nydrazid | TB Prophylaxis | | X | | | For tuberculin converters who do not have active TB; Minimum 72 hrs ground trial. |
| Gen | Ketamine | Ketalar | Anesthesia | | | X | | Minimum 48hr DNIA/C required. Counsel members prior to elective dental or surgical procedures to request a alternate anesthetic. |
| Ophth | Ketotifen | Zaditor | Itching and redness in the eyes due to allergies | | | X | | |
| Ophthal | Latanoprost Drops | Xalatan | Glaucoma | | | X | | DNIA/C until potential for idiosyncratic reaction has been ruled out. Underlying condition may require waiver in which case, DNIA/C until waiver approved. |
| Ophthal | Levobunolol Drops | Betagan | Glaucoma | | | X | | DNIA/C until potential for idiosyncratic reaction has been ruled out. Underlying condition may require waiver in which case, DNIA/C until waiver approved. |
| Pulm | Levalbuterol | Xopenex | Asthma | | | | X | DNIA/C until potential for idiosyncratic reaction has been ruled out and control is maintained, then submit for waiver. Requires MEB submission prior to waiver. |
| Gen | Levothyroxine | Synthroid | Hypothyroidism or Thyroid Suppression | | | X | | DNIA/C until potential for idiosyncratic reaction has been ruled out and all symptoms resolved. IRILO and waiver required if hypothyroidism is due the thyroid cancer treatment. |
| ENT | Loratadine | Claritin | Allergy | | | X | | Minimum 72 hrs ground trial at initiation of therapy and symptoms controlled. Maximum dosage is limited to 10 mg per day. |
| Gen | Mesalamine (complexed with methyl/methacrylic acid resin) | Asacol | Inflammatory Bowel Disorder | | | | X | DNIA/C until symptoms are controlled and minimum observation period is met for level of disease (see AMCB Minutes Paragraph 4g), then submit for waiver. |
| Gen | Mesalamine (delayed release via polymer) | Lialda | Inflammatory Bowel Disorder | | | | X | Submit for waiver after potential for idiosyncratic reaction has been ruled out and control is maintained. See Waiver Guide. |

| Category | Medication | | Diagnosis or Utilization | No DNIA/C Or Waiver | DNIA/C (No Waiver Required) | | DNIA/C (Waiver Required) | Notes |
|----------|--|---|---|---------------------|-----------------------------|--------------------------------------|--------------------------|--|
| | Generic Name (Oral Preparation Unless Specified Otherwise) | Trade Name (Not Inclusive) | | | For Ground Trial | Symptoms Controlled (No Side Effect) | | |
| Gen | Mesalamine (complexed with ethyl cellulose) | Pentasa | Inflammatory Bowel Disorder | | | | X | DNIA/C until symptoms are controlled and minimum observation period is met for level of disease (see AMCB Minutes Paragraph 4g), then submit for waiver. |
| Gen | Mesalamine (enema/ suppositories) | Rowasa | Inflammatory Bowel Disorder | | | | X | DNIA/C until symptoms are controlled and minimum observation period is met for level of disease (see AMCB Minutes Paragraph 4g), then submit for waiver. |
| Endo | Metformin | Glucophage | Diabetes Mellitus, pre-diabetes (includes impaired fasting glucose) | | | | X | Submit for waiver after patient has been on medication for at least 30 days and the requirements for waiver submission (as defined by the Diabetes Waiver Guide) have been met. |
| GU | Metformin | Glucophage | Polycystic Ovarian Syndrome | | | X | | DNIA/C until potential for idiosyncratic reaction has been ruled out and symptoms are well controlled. |
| Derm | Metronidazole (Topical) | Flagyl | Rosacea | X | | | | DNIA/C not required unless condition or medication interferes with duties. |
| GU | Metronidazole (Topical) | Flagyl | Vaginitis | X | | | | DNIA/C is not required for occasional OTC use to provide relief from minor self-limiting conditions unless underlying condition is symptomatic and interferes with duties. |
| Derm | Minoxidil (Topical) | Rogaine | Hair loss | X | | | | Topical use only. |
| ENT | Montelukast | Singulair | Allergic Rhinitis Urticaria | | | X | | Third line agent after non-sedating antihistamines and nasal steroid spray. DNIA/C until potential for idiosyncratic reaction has been ruled out and control is maintained. |
| ENT | Montelukast | Singulair | Asthma, broncho-constriction | | | | X | IRILO/MEB required for asthma, then submit waiver. |
| Gen | Nicotine Gum | Nicorette | Tobacco Addiction | X | | | | |
| Gen | Nicotine Inhaler | Nicotrol | Tobacco Addiction | X | | | | |
| Gen | Nicotine Patch | NicoDerm | Tobacco Addiction | X | | | | |
| Gen | Nifedipine Coat Core Nifedipine GITS | Adalat CC Procardia XL | Hypertension | | | | X | Submit for waiver after potential for idiosyncratic reaction has been ruled out and control is maintained. Minimum 7-day observation after last dose adjustment. NOTE: NO OTHER FORMULATIONS OF NIFEDIPINE ARE COVERED UNDER THIS POLICY. Nifedipine Background Paper |
| Gen | NSAIDs (not Toradol) | Celebrex, Daypro, Indocin, Lodine, Mobic, Motrin, Relafen, Voltaren | Pain (chronic use) | | | X | | DNIA/C until potential for idiosyncratic reaction has been ruled out and pain/inflammation control is achieved. Consider underlying condition and potential for distraction due to pain. |
| Gen | NSAIDs (not Toradol) | Same as for Chronic pain | Pain (acute use) | X | | | | DNIA/C is not required for occasional (not regularly scheduled) use to provide relief from minor self-limiting conditions. |
| Ophthal | Olopatadine Eye Drops | Patanol | Allergic Conjunctivitis | | | X | | Do not prescribe if member uses contact lenses. DNIF until potential for idiosyncratic reaction has been ruled out (minimum 3 days) and symptom control is maintained. |

| Category | Medication | | Diagnosis or Utilization | No DNIA/C Or Waiver | DNIA/C (No Waiver Required) | | DNIA/C (Waiver Required) | Notes |
|----------|--|--------------------------------|--|---------------------|-----------------------------|--------------------------------------|--------------------------|--|
| | Generic Name (Oral Preparation Unless Specified Otherwise) | Trade Name (Not Inclusive) | | | For Ground Trial | Symptoms Controlled (No Side Effect) | | |
| Gen | Oseltamivir | Tamiflu | Influenza Prophylaxis (2 nd Line) | | X | | | For unvaccinated personnel during community outbreaks or mission essential operations IAW MAJCOM policy ; Requires 1-day ground trial; Oseltamivir Background Paper |
| Gen | Oseltamivir | Tamiflu | Influenza Treatment | | | X | | DNIA/C until the potential for idiosyncratic reaction has been ruled out and underlying condition does not interfere with duties; Oseltamivir Background Paper |
| Derm | Pediculicide/ Scabicide | Elimite, Eurax, Lindane cream | Scabies | | | X | | DNIA/C until the potential for idiosyncratic reaction has been ruled out and underlying condition does not interfere with duties. |
| GU | Phenazopyridine | Pyridium | UTI | X | | | | |
| Derm | Pimecrolimus 1% Cream (Topical) | Elidel | Atopic Dermatitis | X | | | | DNIA/C not required unless condition or medication interferes with duties Pimecrolimus Background Paper . |
| Derm | Podofilox (Topical) | Condylox | Warts | X | | | | DNIA/C not required unless condition or medication interferes with duties. |
| GU | Potassium Citrate | Urocit-K | Urolithiasis | | | | X | Submit for waiver after potential for idiosyncratic reaction has been ruled out and control is maintained. Minimum 7-day observation after last dose adjustment. |
| Gen | Primaquine | Primaquine | Malaria Prophylaxis (Terminal Phase) | | X | | | Single dose ground trial required; 30 mg (base) daily (recommendation for increase from 15 mg to 30 mg by CDC) for terminal 14 days of post-exposure prophylaxis; Contraindication: G-6-PD deficiency, pregnancy, and possibly lactation (if infant has G-6-PD deficiency) |
| MS | Probenecid | Benemid | Gout or Hyperuricemia | | | X | | Alone or in combination with thiazide (hydrochlorothiazide or chlorothiazide); DNIA/C until potential for idiosyncratic reaction has been ruled out and control is maintained |
| Gen | Potassium Iodide | Thyroshield, ThyroSafe, Iostat | Radiation chemoprophylaxis | | X | | | 8 hour ground trial prior to first expected use (as operations allow). Do not prescribe for Airmen with known iodine sensitivity, thyroiditis, goiter, hyperkalemia, or pregnancy. Do not ground test unless use is anticipated/directed by MAJCOM or COCOM. Document ground test in ASIMS. |
| GU | Progestin (Injectable) | Depo-Provera/Norplant | Contraception | | X | | | Minimum 7-days ground trial is required; changes of dosage or preparation requires an additional 7-day observation period. |
| GU | Progestin (Implantable Timed Released) | Mirena | Contraception | | X | | | Minimum 7-days ground trial is required; changes of dosage or preparation requires an additional 7-day observation period. |
| Gen | Proguanil/ Atovaquone (Combination) | Malarone | Malaria Prophylaxis (2 nd Line) | | X | | | Single dose ground trial required; Malarone (250 mg atovaquone/100 mg proguanil) daily beginning 1-2 days prior to travel; ending 7 days after exposure (Reminder: last 7 days of Malarone should be taken with primaquine followed by another 7 days of primaquine alone); Malarone Background Paper |

| Category | Medication | | Diagnosis or Utilization | No DNIA/C Or Waiver | DNIA/C (No Waiver Required) | | DNIA/C (Waiver Required) | Notes |
|----------|--|--|--|---------------------|-----------------------------|--------------------------------------|--------------------------|---|
| | Generic Name (Oral Preparation Unless Specified Otherwise) | Trade Name (Not Inclusive) | | | For Ground Trial | Symptoms Controlled (No Side Effect) | | |
| Neuro | Pyridostigmine | Mestinon | CW Prophylaxis | | X | | | DNIA/C until potential idiosyncratic reactions has been ruled out; Use IAW with operational guidance ; Single dose ground trial advised. |
| Onc | Raloxifene | Evista | Breast Cancer prophylaxis | | | | X | Use for breast cancer chemoprophylaxis in coordination with a specialist experienced in breast cancer chemoprophylaxis only. All other uses require review on case-by-case basis. Submit for waiver after at least 1 month and stable on therapy. See Raloxifene Paper . |
| Gen | Resin Binding Agent | | Hyperlipidemia | | X | | | DNIF until potential for idiosyncratic reaction has been ruled out. |
| Pulm | Rifampin | | TB Prophylaxis | | X | | | For tuberculin converters who do not have active TB, minimum 72 hours ground trial. |
| Neuro | Ropinirole | Requip | Restless Legs Syndrome | | | | X | DNIA/C for first 30 days of use (minimum). |
| Gen | Scopolamine/ Dextroamphetamine | Scop/Dex | Airsickness | | | X | | Alone or in combination with dextroamphetamine for airsickness during transport to launch facility. |
| Psych | Sertraline | Zoloft | Depression | | | | X | Max dose 200 mg/day. Waiver will not be considered until member is on medication with stable dose and clinically asymptomatic for at least six months. |
| GU | Sildenafil | Viagra | Erectile Dysfunction | | X | | | 24 hours grounding required after each dosage (Verbal DNIA/C acceptable). Not authorized for daily use. |
| GU | Sildenafil | Rapaflo | BPH | | | X | | Maximum dose 8 mg daily. See Sildenafil Paper . First line agent for BPH. No waiver required. |
| Gen | Spironolactone | Aldactone | Hirsutism, Hyperaldosteronism (2nd line) | | | | X | Submit for waiver after potential for idiosyncratic reaction has been ruled out and control is maintained. Eplerenone and Spironolactone Background Paper . |
| Gen | Statin Derivatives | Simvastatin, Pravastatin, Lovastatin, Rosuvastatin, Atorvastatin | Hyperlipidemia | | X | | | Waiver not required if on single approved statin medication for hyperlipidemia. Approved medications include simvastatin, pravastatin, lovastatin and rosuvastatin up to 40 mg/day and atorvastatin up to 80 mg/day. Higher doses or combination of medication requires waiver. Requires at least 5 day ground trail when starting medication or for any adjustments to dosage to rule out idiosyncratic reactions. Follow up of lipids and LFTs should conform to accepted practice standards. |
| Pulm | Steroids (Inhaled orally) | | Asthma | | | | X | All inhaled corticosteroids approved for use in asthma by the FDA as of 13 May 2012 may be used. Submit for waiver after potential for idiosyncratic reaction has been ruled out and control is maintained. Requires IRILO/MEB submission prior to waiver. Combination with long acting beta-agonists is not waivable. |

| Category | Medication | | Diagnosis or Utilization | No DNIA/C Or Waiver | DNIA/C (No Waiver Required) | | DNIA/C (Waiver Required) | Notes |
|----------|--|----------------------------|---|---------------------|-----------------------------|--------------------------------------|--------------------------|---|
| | Generic Name (Oral Preparation Unless Specified Otherwise) | Trade Name (Not Inclusive) | | | For Ground Trial | Symptoms Controlled (No Side Effect) | | |
| GI | Steroids (metered-dose inhaler) | | Eosinophilic Esophagitis | | | | X | Topical corticosteroid therapy, administered via metered-dose inhaler (swallowed), is approved for treatment of eosinophilic esophagitis. Submit for waiver after potential for idiosyncratic reaction has been ruled out and control is maintained – see EoE Waiver Guide . |
| ENT | Steroids (Nasal) | | Allergic rhinitis, non-allergic nasal symptoms | | | X | | DNIA/C until potential for idiosyncratic reaction has been ruled out and control is maintained. |
| Derm | Steroids (Topical) | | Rash or Skin Diseases | X | | | | DNIA/C not required unless condition or medication interferes with duties. If used for a chronic condition, the underlying diagnosis may require a waiver. |
| GI | Sucralfate | Carafate | Prevention of Recurrent, Uncomplicated Duodenal Ulcer | | | X | | 1 gram once daily; DNIA/C until potential for idiosyncratic reaction has been ruled out and control is maintained. |
| Rheum | Sulfasalazine | Azulfidine | Reactive Arthritis Rheumatoid Arthritis | | | | X | Submit for waiver after potential for idiosyncratic reaction has been ruled out and control is maintained. Only authorized for RA cases that show no progression of disease (only 10% of cases). Mesalamine is better choice for inflammatory bowel disease control. Requires IRILO/MEB. |
| GU | Tadalafil | Cialis | Erectile Dysfunction | | X | | | 24 hours grounding required after each dosage (Verbal DNIA/C acceptable). Not authorized for daily use. |
| GU | Tamsulosin | Flomax | BPH | | | | X | Minimum 7-day ground trial. A dose adjustment also requires a 7 day observation period. Repaflo is first line agent not requiring waiver. |
| Derm | Tazarotene 0.1% Gel (topical) | Tazorac | Acne Vulgaris | | X | | | Tazarotene Background Paper |
| Derm | Tazarotene 0.05% and 0.1% Gel (topical) | Tazorac | Psoriasis | | X | | | Tazarotene Background Paper |
| Derm | Terbinafine | Lamisil | Fungal Infection | | X | | | For treatment of fungal culture or formal histopathologically confirmed fungal infections only (positive KOH is <u>not</u> acceptable); DNIA/C for 72 hrs ground trial and obtain baseline LFTs; 250 mg daily for 12 weeks; Terbinafine Background Paper . |
| GU | Testosterone and Estrogen (combination) | Estratest | Hormone Replacement Therapy (menopause) | | | X | | Minimum of 7-days ground trial is required; changes of dosages and/or preparation requires an additional 7-day observation period. |
| GU | Testosterone (Injectable) | | Hormone Replacement Therapy | | | | X | Appropriate urological work-up is required prior to starting medication. Minimum of 7-days ground trial, control of manifested symptoms are maintained, requires IRILO/MEB prior to waiver approval, then submit for waiver. A change of dosages and/or preparation requires an additional 7-day observation period. (Note: Testosterone has been classified as a Schedule 3 Controlled Drug.) |

| Category | Medication | | Diagnosis or Utilization | No DNIA/C Or Waiver | DNIA/C (No Waiver Required) | | DNIA/C (Waiver Required) | Notes |
|----------|--|----------------------------|---|---------------------|-----------------------------|--------------------------------------|--------------------------|--|
| | Generic Name (Oral Preparation Unless Specified Otherwise) | Trade Name (Not Inclusive) | | | For Ground Trial | Symptoms Controlled (No Side Effect) | | |
| GU | Testosterone (Transdermal) | | Hormone Replacement Therapy | | | | X | Appropriate urological work-up is required prior to starting medication. Minimum of 7-days ground trial, control of manifested symptoms are maintained, requires IRILO/MEB prior to waiver approval, then submit for waiver. A change of dosages and/or preparation requires an additional 7-day observation period. (Note: Testosterone has been classified as a Schedule 3 Controlled Drug) |
| Derm | Tetracycline | Sumycin | Acne | | X | | | DNIA/C until potential for idiosyncratic reaction has been ruled out and control is maintained. |
| GU | Tetracycline | Sumycin | Suppressive Therapy for Chronic or Recurrent Prostatitis / Cystitis | | | X | | DNIA/C until potential for idiosyncratic reaction has been ruled out and control is maintained. |
| Ophthal | Timolol Drops | Timoptic | Glaucoma | | | X | | DNIA/C until potential for idiosyncratic reaction has been ruled out. Underlying condition may require waiver in which case, DNIA/C until waiver approved. |
| Neuro | Topiramate | Topamax | Migraines (only) | | | | X | DNIA/C for first 30 days of use (minimum) and control is maintained and no side effects, then submit for waiver |
| Derm | Tretinoin (Topical) | Retin-A | Acne | X | | | | DNIA/C not required unless condition or medication interferes with duties. |
| GU | Trimethoprim-Sulfamethoxazole (TMP/SMX) | Bactrim Septra | Suppressive Therapy for Chronic or Recurrent Prostatitis / Cystitis | | | X | | DNIA/C until potential for idiosyncratic reaction has been ruled out and control is maintained, then submit for waiver. |
| Neuro | Triptan class of medicines | Maxalt Relpax Imitrex | Migraines | | | | X | Non-injection formulations only. Submit for waiver after potential for idiosyncratic reaction has been ruled out and control is maintained. Efficacy and tolerance of triptan on at least 2 migraine episodes must be documented. See Headache Waiver Guide for additional details. |
| Derm | Valacyclovir | Valtrex | HSV Suppression | | X | | | DNIA/C until potential for idiosyncratic reaction has been ruled out. |
| GU | Vardenafil | Levitra | Erectile Dysfunction | | X | | | 24 hours grounding required after each dosage (Verbal DNIA/C acceptable). Not authorized for daily use. |

| Category | Medication | | Diagnosis or Utilization | No DNIA/C or Waiver | DNIA/C (No Waiver Required) | | DNIA/C (Waiver Required) | Not Waiverable | Notes |
|----------|--|----------------------------|--------------------------|---------------------|-----------------------------|--------------------------------------|--------------------------|----------------|---|
| | Generic Name (Oral Preparation Unless Specified Otherwise) | Trade Name (Not Inclusive) | | | For Ground Trial | Symptoms Controlled (No Side Effect) | | | |
| Toxin | Botulinum Toxin | Botox | Cosmetic | | | | | X | When used for facial cosmetic purposes, side effects may include visual blurring, ptosis, corneal ulceration and diplopia. For treatment of non-cosmetic issues, ACS eval is required. |
| Gen | Depo-Medrol | | Allergy | | | | | X | Conidition requiring injectable steroid is reasons for grounding. |
| Derm | Isotretinoin | Accutane | Acne | | | | | X | Anxiety, irritability, anger, and/or depression |
| Gen | Mefloquine | Lariam | Malaria Prophylaxis | | | | | X | Adverse effects include but not limited to: optic neuritis, cataracts, decreased night vision, blurred vision and photosensitivity, pseudotumor cerebri, depression, psychosis, and suicide |
| Gen | Melatonin | | Insomnia | | | | | X | Nightmares, headaches, morning grogginess, and mild depression |
| Derm | Minocycline | Minocin | Acne | | | | | X | Unacceptable (up to 70%) incidence of vestibular side-effects |
| Gen | Varenicline | □ □ Chantix | Smoking Cessation | | | | | X | Irritability, suicidal ideation, aggressive and erratic behavior, cardiac dysrhythmias and sudden death |

Non-Waiverable Medications On This Page